Malignant pleural effusion (PE) is a frequent. Diagnostic Value of CYFRA 21 1 Tumor Marker and CEA in Pleural Effusion Due to Mesothelioma*
|
|
- Jared Barker
- 8 years ago
- Views:
Transcription
1 Diagnostic Value of CYFRA 21 1 Tumor Marker and CEA in Pleural Effusion Due to Mesothelioma* Michela Paganuzzi, PhD; Marina Onetto, MD; Paola Marroni, PhD; Rosa Filiberti, PhD; Elisabetta Tassara, MD; Stefano Parodi, PhD; and Raffaella Felletti, MD Study objective: The aim of our study was to assess the clinical value of CYFRA 21 1 tumor marker and carcinoembryonic antigen (CEA) as diagnostic tools that are complementary to cytology in the diagnosis of malignant mesotheliomas. Patients: We measured CEA and CYFRA 21 1 in the pleural effusions (PEs) and serum of 106 patients (benign lung disease, 34 patients; bronchogenic and metastatic carcinoma, 40 patients; mesothelioma, 32 patients). Methods: CEA and CYFRA 21 1 levels were determined by means of two commercial enzyme immunoassays. Results: The cutoff levels of CYFRA 21 1 and CEA in malignant PEs, selected on the basis of the best diagnostic efficacy, were 41.9 ng/ml and 5.0 ng/ml, respectively. In all neoplastic PEs, CYFRA 21 1 and CEA sensitivity was 78% and 30.6%, respectively, with a specificity of 80% and 91%, respectively. The sensitivity of CYFRA 21 1 and CEA in patients with mesothelioma was 87.5% and 3.1%, respectively. The results of the CYFRA 21 1 assay were positive in 17 of 19 cases of mesothelioma (89.5%) with a negative or uncertain cytology. The association of the tumor marker assay and the cytology allowed a correct diagnosis in 30 of 32 cases of mesothelioma (93.7%). Conclusion: This study suggests that CYFRA 21 1 would provide a useful parameter for the differential diagnosis between benign and malignant PE from mesothelioma when the result of cytology is negative or uncertain and the clinical context does not allow a more aggressive approach. Moreover, the association of CYFRA 21 1 with CEA could provide details for a differential diagnosis between mesotheliomas and carcinomas. In fact, an elevated CYFRA 21 1 level with a low CEA level is highly suggestive of mesothelioma, whereas high levels of CEA alone or high levels of both the markers suggest a diagnosis of malignant PE, excluding mesothelioma. (CHEST 2001; 119: ) Key words: CEA; CYFRA 21 1; mesothelioma; pleural effusion; tumor marker Abbreviations: CEA carcinoembryonic antigen; PE pleural effusion; ROC receiver operating characteristic Malignant pleural effusion (PE) is a frequent occurrence in patients with cancer and may be either a sign of the disease or a complication of an already diagnosed malignancy. 1 Virtually all primary malignancies have been reported to metastasize to the pleura. Some reports suggest that as many as 50% of patients with lung or *From the Clinical Pathology Laboratory (Drs. Paganuzzi, Onetto, and Marroni), the Department of Environmental Epidemiology (Drs. Filiberti and Parodi), and the Thoracic Endoscopy Service (Dr. Tassara), National Institute for Cancer Research, Genoa, Italy; and the Department of Respiratory Disease (Dr. Felletti), A.O. San Martino Hospital, Genoa, Italy. Manuscript received February 10, 2000; revision accepted October 17, Correspondence to: Michela Paganuzzi, PhD, Clinical Pathology Laboratory, National Institute for Cancer Research, Largo R. Benzi 10, Genoa, Italy; patclin@hp380.ist.unige.it breast cancer will develop PEs at some time during the course of their disease. 2 The sine qua non condition for the diagnosis of malignant PE is the cytologic demonstration of malignant cells in pleural fluid; the absence of malignant cells, however, does not exclude malignancy. The difficulties arise in differentiating benign reactive mesothelial cells from malignant mesothelioma cells and metastatic carcinoma cells. 3 Blind pleural biopsy, which is the alternative method in the case of negative cytology results, performs poorly and has a low sensitivity (from 35 to 65%). 4,5 The recent introduction of videothoracoscopy has improved the efficacy of both the diagnosis and treatment of malignant PE. 6 However, it is burdened with the risk for complications such as 1138 Clinical Investigations
2 pneumothorax, pleural shock, hemothorax, and subcutaneous emphysema, as well as possible cancer implantation in 4% of patients. 7 Furthermore, videothoracoscopy with multiple pleural biopsies is an aggressive and expensive method of investigation, and is not available everywhere. The clinical value of serum tumor markers for diagnosis, follow-up, and treatment monitoring of lung cancer patients already has been demonstrated in many studies. 8,9 The measurement of tumor markers in PE represents an effort to improve effectiveness of the differential diagnosis of neoplastic effusions. Several authors have demonstrated the clinical usefulness of measuring different tumor markers in the diagnosis of malignant PE. Those reported series, however, included mostly cases of adenocarcinoma and only a few cases of mesothelioma. The incidence of this neoplasia is relatively low, but it is increasing in certain geographic areas mostly because of an intensive occupational exposure to asbestos. 14 In our region, the incidence of malignant mesothelioma is high, and it is one of the highest values in Europe, with an age-standardized rate of 5.0 per 100,000 men and 0.9 per 100,000 women. 15 In the present study, we aimed to assess the clinical value of CYFRA 21 1 tumor marker and carcinoembryonic antigen (CEA) as diagnostic tools that are complementary to cytologic findings in the diagnosis of malignant mesotheliomas. For this purpose, we measured the tumor markers in the serum and PE of patients with mesothelioma and compared them with those of patients with pleural metastatic carcinoma and benign pathologic conditions. Patients Materials and Methods We measured CEA and CYFRA 21 1 in the serum and PE of 106 consecutive patients admitted for diagnosis to the Department of Respiratory Disease of San Martino Hospital and to the Thoracic Endoscopy Service of the National Institute for Cancer Research of Genoa from 1995 to Informed consent was obtained from all the subjects. Thirty-four patients had benign PE, and 72 patients had malignant PE. Of these latter patients, 32 malignant PEs were from mesothelioma (Table 1). All the PEs were examined through cytologic analysis. When the result of the cytologic examination was negative or in doubt, patients underwent blind pleural biopsies and/or thoracoscopic-guided biopsies. The PEs were considered to be positive according to the presence of malignant cells as determined by cytologic analysis and/or pleural biopsy. The diagnosis of benign disease was confirmed on the basis of instrumental investigations (CT scan), bacteriologic examination, response to therapy, and clinical follow-up. Tumor Marker Assays PEs and blood samples were centrifuged, and aliquots of supernatants and sera were stored at 80 C until tested. CYFRA 21 1 and CEA were measured using two commercially available immunoenzymatic kits. CYFRA 21 1 was measured with a semiautomated system (model ES 300; Boehringer Mannheim; Mannheim, Germany) using a two-step sandwich method with the streptavidin-biotin technique. The assay utilized two mouse monoclonal antibodies, KS 19 1 and BM 19 21, that were directed against two different epitopes of a soluble fragment of cytokeratin 19. CEA was measured using a kit (AXSYM CEA kit; Abbott Laboratories; Abbott Park, IL) that is based on the microparticle enzyme immunoassay technology. The assay of each marker was performed according to the protocol recommended by the manufacturer. Results were expressed in nanograms per milliliter. Statistical Analysis Table 1 Description of Patients Diagnosis Differences in the median values between the groups under study were checked using the Kruskall-Wallis test, while the Mann-Whitney U test was used for comparison of the two groups. Spearman rank correlation coefficients for the tumor markers were calculated separately for the serum and the PE. The threshold for each marker was selected on the basis of the best diagnostic efficacy (ie, on the basis of the more equilibrated combination of sensitivity and specificity). In order to compare the performance of the tumor markers, receiver operating characteristic (ROC) curves were constructed. Results Patients, No. Mesothelioma 32 Pleural metastatic carcinoma 40 Lung adenocarcinoma 13 Small-cell lung carcinoma 1 Squamous cell lung carcinoma 2 Lung tumor* 7 Metastasis from adenocarcinoma 17 Benign lung disease 34 Tuberculosis 6 Pleurisy 19 Cardiac failure 3 Liver cirrhosis 2 Other 4 Total 106 *Lung tumors not histologically defined. Includes patients with metastases of the breast (6), stomach (2), colon (2), pancreas (1), uterus (1), ovary (3), parotid gland (1), and kidney (1). Diseases include posttraumatic injury (1), pulmonary embolism (1), asbestosis (1), and empyema (1). The median concentration and range of CEA and CYFRA 21 1 in the serum and PE of patients with malignant and benign disease are reported in Table 2. The PE CYFRA 21 1 concentration was significantly higher in patients with mesothelioma than in CHEST / 119 / 4/ APRIL,
3 Table 2 CYFRA 21-1 and CEA Levels in PE and Serum in Neoplastic and Benign Diseases* Marker Mesothelioma Lung Carcinoma Pleural Metastasis Benign Disease Serum, ng/ml CEA 1.3 ( ) 2.2 ( ) 2.6 (0.6 3,202) 1.7 ( ) CYFRA (1.2 84) 5.1 ( ) 7.0 ( ) 2.5 ( ) PE, ng/ml CEA 0.8 (0.2 7) 6.3 (0.2 1,465.2) 6.0 (0.4 43,850) 1.2 ( ) CYFRA (10.1 5,180) 75.0 (7.7 3,198) 94.2 (4.1 26,750) 21.7 ( ) *Values are given as the median (minimum to maximum values). those with benign pleurisy (p 0.001) and with carcinoma (p 0.02). In serum, a significant difference was observed between patients with mesotheliomas and benign diseases (p ), but not those with carcinomas. The CEA values both in the serum and in PE were significantly higher in patients with carcinomas than in those with mesotheliomas (p 0.001). The distribution of CYFRA 21 1 and CEA in PEs is shown in Figure 1. The ROC curves analysis showed the performance of PE CYFRA 21 1 and CEA in mesotheliomas (Fig 2). We evaluated the diagnostic efficacies in serum and PE for CYFRA 21 1 and CEA in all malignancies at different cutoff levels. The sensitivity of the two markers was higher in PEs than in sera (not significant) at any cutoff level. The best diagnostic efficacy of CYFRA 21 1 in PEs (78%) was observed at the cutoff value of 41.9 ng/ml, which achieved a sensitivity of 78% and a specificity of 80%. The sensitivity in patients with carcinomas was 67.5%, and in those with mesotheliomas it was 87.5%. For CEA, we chose the diagnostic accuracy (49%) obtained with the conventional cutoff of 5.0 ng/ml. The sensitivity was 30.6% in all malignancies, 52.5% in carcinomas, and 3.1% in mesotheliomas, with a specificity of 91% (Table 3). The performance of CEA and CYFRA 21 1 in PEs was compared with the cytologic analysis. Forty of the 72 patients with neoplastic disease (55.6%) had negative results of cytologic analysis, 26 patients (36.1%) had positive results, and 6 patients (8.3%) had uncertain behavior. The positivity of CEA and CYFRA 21 1 in the 46 patients with negative or uncertain cytologic analysis results is reported in Table 4. Considering mesotheliomas alone, 13 patients (41%) had positive results of cytologic analysis, 16 patients (50%) had negative results, and 3 patients (9%) had uncertain behavior. Seventeen of 19 patients (89.5%) with negative or uncertain results of cytologic analysis showed positive CYFRA 21 1 concentrations. Figure 1. Distribution of CEA and CYFRA 21 1 concentrations in PEs from carcinomas (F), mesotheliomas (Œ), and benign diseases (E). The cutoff values (CEA, 5.0 ng/ml; CYFRA 21 1, 41.9 ng/ml) are denoted by horizontal and vertical lines, respectively. Figure 2. ROC curves of CEA and CYFRA 21 1 in the differential diagnosis between mesotheliomas and benign PEs Clinical Investigations
4 Table 3 Diagnostic Sensitivity of CEA and CYFRA 21-1 in PEs* Disease CEA, % CYFRA 21-1, % All malignancies Carcinomas Lung carcinomas Pleural metastases Mesotheliomas *The cutoff level for CEA is 5 ng/ml, and that for CYFRA 21-1 is 41.9 ng/ml. The specificity at these cutoff values was 91% for CEA and 80% for CYFRA The cytologic examination combined with the measurement of PE CEA and CYFRA 21 1 increased the detection rate of mesotheliomas to 93.7%. Discussion The differential diagnosis between benign and malignant effusions represents a critical clinical problem. Cytologic analysis is the method usually adopted to identify malignant cells in a PE, but it seems not to be sensitive enough (40 to 60%). 3 In the case of uncertainty, blind or thoracoscopic-guided biopsy should be used. This procedure is highly sensitive, but, unfortunately, it is also invasive and limited to specialized centers. The results of previous studies have suggested that a pool of different markers in the PE can improve the diagnostic power of cytologic analysis in detecting malignant PEs CEA was found to be a complementary tool to immunohistochemical studies for differentiating between PEs resulting from metastatic tumors and from malignant mesothelioma. 13,19 The CYFRA 21 1 assay, which detects a soluble fragment of cytokeratin 19 that is expressed by all histologic types of lung cancer, 20 was indicated as the most available tumor marker in PEs from epithelial carcinomas, especially squamous cell carcinomas. 11,21 Overall, our findings agree with those of other Table 4 Cases Showing CEA and/or CYFRA 21-1 Values Higher Than the Cutoff Threshold in the 46 Malignant PEs With Negative or Uncertain Cytology Results* Malignancies Patients, No. CEA CYFRA 21-1 CEA and/or CYFRA 21-1 Lung carcinomas Pleural metastases Mesotheliomas Total *See Table 3 and text for cutoff levels, specificity, and sensitivity. authors. No correlation was found between CEA and CYFRA 21 1 values, thus confirming that the two molecules provide different information on tumor behavior. Both CEA and CYFRA 21 1 showed a higher sensitivity in PE than in serum, probably because in a limited district tumor markers have concentrations higher than those in the blood stream. Therefore, the diagnosis of malignant PEs could be better achieved by measuring tumor markers in pleural fluid than in serum. The sensitivity of CEA was 30.6% in all malignant effusions and 52.5% in carcinomatous effusions. These percentages of sensitivity were lower than those described in some previous studies, 19,22,23 probably because of the prevalence in our series of patients with mesotheliomas over those with carcinomas. Only one of the mesothelioma patients (3.1%) showed CEA levels higher than the cutoff level. The cytologic analysis in a mesothelioma PE can be challenging even for a trained pathologist. Reviewing the literature, we could find only a few studies on tumor markers in PEs from mesothelioma, which were based on very small groups of patients 13,24 Because of a large number of mesothelioma cases in our series (32 patients), we were better able to define the diagnostic significance of CYFRA 21 1 and CEA in such a difficult diagnosis. CYFRA 21 1 sensitivity was significantly higher in patients with mesotheliomas than in those with carcinomas. In agreement with our results, other authors 24,25 have reported that mesothelioma cells expressed very high levels of cytokeratin 19 and that high levels of tissue polypeptide antigen (cytokeratins 8, 18, and 19) were present in the pleural fluid of patients with mesotheliomas. Salama et al, 24 in a series of nine mesothelioma patients, attributed a great clinical value to CYFRA 21 1 in the diagnosis of the disease. As reported by this author and others, 26,27 we found that high CYFRA 21 1 levels and low CEA levels are associated with mesothelioma. Because some lung carcinomas showed a similar behavior, the diagnosis of mesothelioma on the basis of this profile should be made with extreme caution. However, in our study, all the mesothelioma patients, except one, showed very low levels of CEA in all PEs. Consequently, we infer that high CYFRA 21 1 levels with low CEA levels are suggestive of mesothelioma, whereas high levels of CEA alone or high levels of both markers can show evidence of malignant PEs, excluding mesothelioma. As reported in the literature, 24 our findings indicated that CEA and CYFRA 21 1 are complementary tools to cytologic analysis in the clinical assessment of malignant PEs, in particular those resulting from mesothelioma. In our study, the cytologic CHEST / 119 / 4/ APRIL,
5 diagnostic sensitivity in mesothelioma PEs was 40.6%. In 19 mesotheliomas with a false-negative or uncertain cytology, the CYFRA 21 1 diagnostic sensitivity was 89%, while no cases showed CEA values higher than the cutoff level. The association of cytology with the measurement of PE CEA and CYFRA 21 1 levels allowed a correct diagnosis of 30 of 32 mesotheliomas (93.7%). In conclusion, when the cytologic analysis does not allow a final PE diagnosis, increased CYFRA 21 1 and/or CEA concentrations may represent, for the clinician, a useful decisional criterion before embarking on a more aggressive approach to treatment. When patients are in good performance status, pleural biopsy and/or thoracoscopy are necessary in order to stage the cancer and plan a correct therapeutic approach. In patients with poor clinical conditions, because of age or low performance status, diagnosis should be made on the basis of tumor markers alone, avoiding more aggressive diagnostic techniques. References 1 Millard FJC, Pepper JR. Pleural disease. In: Brewis RAL, Corrin B, Geddes DM, et al, eds. Respiratory medicine (vol 2). 2nd ed. London, UK: WB Saunders, 1995; Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol 1985; 12: Loddenkemper R. Thoracoscopy-state of the art. Eur Respir J 1998; 11: Prakash UBS, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 1985; 60: Light RW, Eozan YS, Ball WC. Cells in pleural fluid: their value in differential diagnosis. Arch Intern Med 1973; 132: Boutin C, Viallat JR, Cargnino P, et al. Thoracoscopy in malignant pleural effusions. Am Rev Respir Dis 1981; 124: Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med 1991; 114: Plebani M, Basso D, Navaglia F, et al. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 1995; 72: Wieskopf B, Demangeat C, Purohit A, et al. CYFRA 21 1 as a biologic marker of non-small cell lung cancer: evaluation of sensitivity, specificity, and prognosis. Chest 1995; 108: Cascinu S, Del Ferro E, Barbanti I, et al. Tumor markers in the diagnosis of malignant serous effusions. Am J Clin Oncol 1997; 20: Toumbis M, Rasidakis E, Passalidou E, et al. Evaluation of CYFRA 21 1 in malignant and benign pleural effusions. Anticancer Res 1996; 16: Villena V, Lopez-Encuentra A, Echave-Sustaeta J, et al. Diagnostic value of CA 72 4, carcinoembryonic antigen, CA 15 3, and CA 19 9 assay in pleural fluid: a study of 207 patients. Cancer 1996; 78: Ferrer J, Villarino MA, Encabo G, et al. Diagnostic utility of CYFRA21 1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999; 86: Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999; 79: Vercelli M, Orengo MA, Casella C, et al. Ligurian Tumor Registry, period ; In: Parkin DM, Whelan SL, Ferlay J, eds. Cancer incidence in five continents (vol II). Lyon, France: IARC Scientific Publications, Tamura S, Nishigaki T, Moriwaki Y, et al. Tumor markers in pleural effusion diagnosis. Cancer 1988; 61: Toumbis M, Chondros K, Ferderigos AS, et al. Clinical evaluation of four tumor markers in malignant and benign pleural effusions. Anticancer Res 1992; 12: San Jose ME, Alvarez D, Valdes L, et al. Utility of tumor markers in the diagnosis of neoplastic pleural effusion. J Clin Chim Acta 1997; 265: Shijubo N, Honda Y, Fujishima T, et al. Lung surfactant protein-a and carcinoembryogenic antigen in pleural effusions because of lung adenocarcinoma and malignant mesothelioma. Eur Respir J 1995; 8: Lai RS, Hsu HK, Lu JY, et al. CYFRA 21 1 enzyme-linked immunosorbent assay: evaluation as a tumor marker in nonsmall cell lung cancer. Chest 1996; 109: Satoh H, Sumi M, Yagyu H, et al. Clinical evaluation of CYFRA 21 1 in malignant pleural fluids. Oncology 1995; 52: Marel M, Stastny B, Melinova L, et al. Diagnosis of pleural effusions: experience with clinical studies, 1986 to Chest 1995; 107: Loncar R, Ostojic L, Tabakovic Loncar V, et al. Diagnostic potential of carcinoembryonic antigen and ferritine in tuberculous and malignant pleural effusion. Tumori 1995; 81: Salama G, Miedouge M, Rouzaud P, et al. Evaluation of pleural CYFRA 21 1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 1998; 77: Bonfrer JMG, Schouwink JH, Kors CM, et al. CYFRA 21 1 and TPA as markers in malignant mesothelioma. Anticancer Res 1977; 17: Nisman B, Barak V, Heching N, et al. Cytokeratin markers in malignant pleural mesothelioma. Cancer Detect Prev 1998; 22: Mezger J, Lamerz R, Permanetter W. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma. Thorac Cardiovasc Surg 1990; 100: Clinical Investigations
The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion
Malaysian J Path01 2002; 24(1) : 53-58 The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion Pavai STHANESHWAR MD, Sook-Fan YAP FRCPath, FRCPA and Gita JAYARAM MDPath, MRCPath
More informationDIAGNOSTIC VALUE OF CEA, CA-19-9, CA 125 AND CA 15-3 LEVELS IN MALIGNANT PLEURAL FLUIDS
DIAGNOSTIC VALUE OF CEA, CA-19-9, CA 125 AND CA 15-3 LEVELS IN MALIGNANT PLEURAL FLUIDS Gülden Paşaoğlu 1, Adil Zamani 2, Gülsüm Can 3, Oktay İmecik 2 State Hospital of Ulus, Department of Chest Disease
More informationNon-invasive diagnosis of pleural malignancies: The role of tumour markers
Lung Cancer (2008) 59, 350 354 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/lungcan Non-invasive diagnosis of pleural malignancies: The role of tumour markers Michel M.
More informationPractical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
More informationCarbohydrate antigen 19 9 (CA 19 9) (serum, plasma)
Carbohydrate antigen 19 9 (CA 19 9) (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Carbohydrate antigen 19 9 (CA 19 9) 1.2 Alternative names Cancer antigen 19 9, cancer antigen GI
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationDiseases. Inflammations Non-inflammatory pleural effusions Pneumothorax Tumours
Pleura Visceral pleura covers lungs and extends into fissures Parietal pleura limits mediastinum and covers dome of diaphragm and inner aspect of chest wall. Two layers between them (pleural cavity) contains
More informationSurgeons Role in Symptom Management. A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND
Surgeons Role in Symptom Management A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND Conditions PLEURAL Pleural effusion Pneumothorax ENDOBRONCHIAL Haemoptysis
More informationPROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
More informationMost cases of mesothelioma are caused by occupational
Percutaneous Image-Guided Cutting Needle Biopsy of the Pleura in the Diagnosis of Malignant Mesothelioma* Rosie F. Adams, BM BCh; Winifred Gray, MB BS; Robert J. O. Davies, DM; and Fergus V. Gleeson, MB
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationInternational Journal of Case Reports in Medicine
International Journal of Case Reports in Medicine Vol. 2013 (2013), Article ID 409830, 15 minipages. DOI:10.5171/2013.409830 www.ibimapublishing.com Copyright 2013 Andrew Thomas Low, Iain Smith and Simon
More informationOutline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
More informationCytopathology Case Presentation #8
Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationEpidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD
Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of
More informationPleural and Pericardial fluids a one year analysis
Pleural and Pericardial fluids a one year analysis Dr Olafsdottir Dr J Williams Department of Cytology, Llandough Hospital Contents Background Standards Aims/Questions Investigation group Results Conclusions
More informationMale. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
More informationHow To Diagnose And Treat A Tumour In An Effusion
Effusions of the Serous Cavities Annika Dejmek Professor/Consultant in Cytopathology Clinical Pathology; Department of Laboratory Medicine, Malmö, Lund University 5th EFCS Tutorial Trondheim 2012 Pleura
More informationCEA, AFP, CA125, CA153 and CA199 in Malignant Pleural Effusions Predict the Cause
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.1.363 CEA, AFP, CA125, CA153 and CA199 in Malignant Pleural Effusions Predict the Cause RESEARCH ARTICLE CEA, AFP, CA125, CA153 and CA199 in Malignant Pleural
More informationThe develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
More informationDiagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com
More informationNOVEL PLATFORMS FOR CANCER DIAGNOSIS
NOVEL PLATFORMS FOR CANCER DIAGNOSIS Luca Beneduce, Ph.D. Founded in 2001 and headquartered in Venice (Italy) Xeptagen is a privately held biotech company funded by venture capital. Xeptagen s mission
More informationASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3
ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationThe Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin
Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationDisease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200
GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung
More informationUpdate on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationScience Highlights. To PSA or not to PSA: That is the Question.
Science Highlights June 2012 by Ann A. Kiessling, PhD at the To PSA or not to PSA: That is the Question. The current raucous debate over the commonly used PSA blood test to screen for prostate cancer,
More informationCytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%
More informationClinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines
Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
More informationDiagnostic Challenge. Department of Pathology,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
More informationNon Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationSoluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions
Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions Harvey I. Pass, MD, Anil Wali, PhD, Naimei Tang, PhD, Alla Ivanova, PhD, Sergey Ivanov, PhD, Michael Harbut,
More informationGeneral Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014
General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
More informationAsbestos-Related Cancer Research and Prevention
Asbestos-Related Cancer Research and Prevention Professor Nico van Zandwijk Asbestos Diseases Research Institute University of Sydney International Conference on Asbestos Awareness and Management 18 November
More informationPrimary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low
More informationLung cancer. A guide for journalists on Non-Small Cell Lung Cancer (NSCLC) and its treatment
Lung cancer A guide for journalists on Non-Small Cell Lung Cancer (NSCLC) and its treatment Contents Contents 2 3 Section 1: Lung Cancer 4 i. Types of lung cancer 4 ii. Causes and risk factors 5 iii. Symptoms
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationMalignant Pleural Diseases Advances Clinicians Should Know F Gleeson
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant
More informationThoracoscopy in Pleural Malignant Mesothelioma
Diagnostic and Therapeutic Endoscopy, 1997, Vol. 3, pp. 147-151 Reprints available directly from the publisher Photocopying permitted by license only (C) 1997 OPA (Overseas Publishers Association) Amsterdam
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationDOI: 10.1016/j.athoracsur.2007.07.042
Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions Harvey I. Pass, Anil Wali, Naimei Tang, Alla Ivanova, Sergey Ivanov, Michael Harbut, Michele Carbone and Jeffrey
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationMalignant Mesothelioma: A Study of Sixty-Six Cases
ORIGINAL RESEARCH ARTICLE Tanaffos (2006) 5(4), 59-63 2006 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran Malignant Mesothelioma: A Study of Sixty-Six Cases Ali Cheraghvandi
More informationNotice of Faculty Disclosure
The Diagnosis of Malignant Mesothelioma Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada achurg@mail.ubc.ca Notice of Faculty Disclosure In accordance with
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationBlood-Based Cancer Diagnostics
The Biotechnology Education Company Blood-Based Cancer Diagnostics EDVO-Kit 141 Store entire experiment at room temperature. EXPERIMENT OBJECTIVE: The objective of this experiment is to learn and understand
More information1. What is the prostate-specific antigen (PSA) test?
1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor
More informationMalignant Mesothelioma
Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
More informationMalignant Mesothelioma
Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
More informationEvaluation of tumor markers for the differential diagnosis of benign and malignant ascites
ORIGINAL ARTICLE May-June, Vol. 13 No. 3, 2014: 357-363 357 Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites Fang Liu,*, Xinjuan Kong,**, Qian Dou,** Jin Ye,***
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
More informationPRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
More informationLung Cancer: Diagnosis, Staging and Treatment
PATIENT EDUCATION patienteducation.osumc.edu Lung Cancer: Diagnosis, Staging and Treatment Cancer begins in our cells. Cells are the building blocks of our tissues. Tissues make up the organs of the body.
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationCase Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation
Volume 2013, Article ID 198729, 4 pages http://dx.doi.org/10.1155/2013/198729 Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation R. F. Falkenstern-Ge,
More informationYOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
More informationPATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
More informationMesothelioma: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions
More informationHow To Prevent Asbestos Related Diseases
BD5.3 Report of Working Groups Elimination of Asbestos-related Diseases ICOH 2012 March 18, 2012 Cancun Report of WG Elimination of Asbestos-related Diseases Dr. Sherson mail to ICOH President of 7 December
More informationRare Thoracic Tumours
Rare Thoracic Tumours 1. Epithelial Tumour of Trachea 1 1.1 General Results Table 1. Epithelial Tumours of Trachea: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes Incidence Trend EAPC
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More information20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.
Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,
More informationWORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14
WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14 BEFORE: M. Crystal: Vice-Chair HEARING: August 20, 2014 at Toronto Written DATE OF DECISION: December 4, 2014 NEUTRAL CITATION: 2014
More informationWORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 171/08
WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 171/08 BEFORE: M.F. Keil : Vice-Chair M. Christie: Member Representative of Employers M. Ferrari: Member Representative of Workers HEARING:
More informationSurvey of Mesothelioma Associated with Asbestos Exposure in Japan
The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics
More informationEffusions: Mesothelioma and Metastatic Cancers
Effusions: Mesothelioma and Metastatic Cancers Malignant Mesothelioma Incidence: 2,500 cases/year ~60-80% pts with pleural MM relationship with asbestos exposure Other risk factors: radiation, other carcinogens,
More informationE xudative pleural effusions are common in the clinical practice of both respiratory
Original Article Approach to undiagnosed exudative pleural effusion: the diagnostic yield of blind pleural biopsy Mehrdad Solooki (MD, FRCP) *1 Mirmohamad Miri (MD) 2 1- Department of Pulmonary Medicine,
More informationUses and Abuses of Pathology in Asbestos-exposed Populations
Uses and Abuses of Pathology in Asbestos-exposed Populations Jerrold L. Abraham, MD Department of Pathology State University of New York Upstate Medical University Syracuse, NY, 13210 USA The term: Asbestosis,
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationScreening, early referral and treatment for asbestos related cancer
Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung
More informationTherapy of pleural effusions Modern techniques
Therapy of pleural effusions Modern techniques Dr. Melanie Toffel Sugery of the chest Pleural effusion Ethiology In the normal pleural space there is a steady state in which there is a roughly equal rate
More informationThe Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
More informationRecommendations for the Reporting of Pleural Mesothelioma
Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports
More informationA 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
More informationNeoplasms of the LUNG and PLEURA
Neoplasms of the LUNG and PLEURA 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 Case 1 Case Vignette HISTORY:
More informationDevelopments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
More informationLow-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital
Lung Cancer Screening with Low-dose CT Imaging Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Despite recent declines in the incidence of lung cancer related to the
More informationThe Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
More informationRulex s Logic Learning Machines successfully meet biomedical challenges.
Rulex s Logic Learning Machines successfully meet biomedical challenges. Rulex is a predictive analytics platform able to manage and to analyze big amounts of heterogeneous data. With Rulex, it is possible,
More informationExtrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos
More informationTestimony of. Dr. James Crapo. April 26, 2005
Testimony of Dr. James Crapo April 26, 2005 Written Statement of Dr. James D. Crapo, Professor of Medicine, National Jewish Medical and Research Center and University of Colorado Health Sciences Center
More informationPrincipal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
More informationAsbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin Levels
The new england journal of medicine original article Asbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin Levels Harvey I. Pass, M.D., Dan Lott, B.S., Fulvio Lonardo, M.D., Michael Harbut, M.D.,
More informationMESOTELIOMA and CHRYSOTILE
MESOTELIOMA and CHRYSOTILE in RUSSIA Kashansky S.V., Grinberg L.M., Kuzmin S.V., Berdnikov R.B., Berzin S.A. Ekaterinburg Medical Research Center for Prophylaxis and Health Protection in Industrial Workers
More informationOccupational respiratory diseases due to Asbestos. Dirk Dahmann, IGF, Bochum
Occupational respiratory diseases due to Asbestos Dirk Dahmann, IGF, Bochum Contents Introduction Diseases Further Effects Preventive Strategies Conclusion Asbestos minerals Woitowitz, 2003 Imports (+
More informationHEALTH CARE FOR EXPOSURE TO ASBESTOS. 2010 The SafetyNet Centre for Occupational Health and Safety Research Memorial University www.safetynet.mun.
HEALTH CARE FOR PATIENTS WITH EXPOSURE TO ASBESTOS 2010 The SafetyNet Centre for Occupational Health and Safety Research Memorial University www.safetynet.mun.ca HEALTH CARE FOR PATIENTS WITH EXPOSURE
More informationStephen R. Veach, M.D.
Stephen R. Veach, M.D. Memorial Sloan-Kettering Cancer Center International Oncology Programs 160 E. 53 rd Street New York, NY 10022 212-610 610-08780878 - tel 212-308 308-7063 - fax veachs@mskcc.org SCREENING
More informationNational Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28)
National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28) Tracking Information Publication Number Manual Section Number 100-3 190.28 Manual Section Title Tumor Antigen by
More informationSeptember 2008 [KT 168] Sub. Code: 2063 M.D. DEGREE EXAMINATION Branch XVII Tuberculosis and Respiratory Diseases NON-TUBERCULOSIS CHEST DISEASES Common to Part II Paper II - (Old /New/Revised Regulations)
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More information